$9.70
-0.24 (-2.41%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where BCRX is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
53 interventional · 1 expanded access · 21 with posted results
Held by 17 tracked-famous managers (TWO SIGMA INVESTMENTS, LP, MILLENNIUM MANAGEMENT LLC, JANE STREET GROUP, LLC, RENAISSANCE TECHNOLOGIES LLC, AQR CAPITAL MANAGEMENT LLC, +12 more) · FINRA short interest 12.4 days to cover (settled 2026-07-31) · government filings 180d: none disclosed
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| Open-label Berotralstat Access to HAE Patients Previously Enrolled in Berotralstat StudiesNCT04933721Number and proportion of subjects with a treatment-related TEAEOpen-label · Prevention | Phase 3 | Enrolling by invitation | Drug: berotralstat | Hereditary Angioedema, HAE | 139 | Aug 2031 | ≤ 1,838 d | 2025-12-23 |
| A Study of the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of BCX17725NCT06539507Incidence of treatment-emergent adverse events (TEAEs)Randomized · Double-masked · Treatment | Phase 1 | Recruiting | Drug: BCX17725, Placebo | Netherton Syndrome | 78 | Oct 2026 | ≤ 73 d | 2026-06-16 |
| Berotralstat Treatment in Children With Hereditary AngioedemaNCT05453968results2026-02-25Area Under the Plasma Concentration-Time Curve From Time 0 to the Last Measurable Concentration (AUC0-last) of BerotralstatNon-randomized · Open-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Active, not recruiting | Drug: Berotralstat | Hereditary Angioedema, Pediatric | 29 | 2024-09-11actual | — | 2026-02-25 |
| A Study of Avoralstat In Participants With Diabetic Macular EdemaNCT07228559The safety and tolerability of avoralstat in participants with DME. Incidence and severity of ocular (study eye) and systemic treatment emergent adverse events (TEAEs).Open-label · Treatment | Phase 1 | Terminatedsponsor's stated reason: Strategic decision | Drug: avoralstat | Diabetic Macular Edema (DME) | 3 | 2026-04-17actual | — | 2026-05-11 |
| Long-term Safety of BCX9930 in Participants With Paroxysmal Nocturnal HemoglobinuriaNCT05741346results2025-10-24Number of Participants With Treatment-emergent Events (TEAEs)Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BCX9930 | Paroxysmal Nocturnal Hemoglobinuria | 28 | 2025-01-31actual | — | 2025-10-24 |
| Dose Escalation of BCX10013 in Participants with Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT06100900Number of Participants with Treatment-Emergent Adverse Events (TEAEs) and Graded Laboratory Abnormalities, and Changes From Baseline (CFB) in Laboratory Analytes, Vital signs, Electrocardiograms (ECGs), and Physical Examination Findings.Open-label · Treatment | Phase 1 | Completed | Drug: BCX10013 | Paroxysmal Nocturnal Hemoglobinuria | 8 | 2024-12-11actual | — | 2025-01-08 |
| A Long-Term Safety Study of BCX9930 in Participants With Paroxysmal Nocturnal Hemoglobinuria (PNH)NCT04702568results2024-12-13Number of Participants With Treatment Emergent Adverse Events (TEAEs)Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: BCX9930, Eculizumab, Ravulizumab | Paroxysmal Nocturnal Hemoglobinuria, PNH | 19 | 2023-10-04actual | — | 2025-04-13 |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants Not Receiving Other Complement Inhibitor TherapyNCT05116787results2025-01-03Part 1: Change From Baseline in Hemoglobin at Week 12Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: Placebo, BCX9930 monotherapy | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 12 | 2023-09-18actual | — | 2025-01-03 |
| BCX9930 for the Treatment of Paroxysmal Nocturnal Hemoglobinuria (PNH) in Participants With Inadequate Response to C5 Inhibitor TherapyNCT05116774results2025-03-07Part 1: Change From Baseline in Hemoglobin at Week 24Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor decision | Drug: Eculizumab, Ravulizumab, BCX9930 | Paroxysmal Nocturnal Hemoglobinuria (PNH) | 12 | 2023-09-14actual | — | 2025-03-07 |
| Study to Evaluate the Safety, Tolerability of BCX9930 in Participants With Either Complement 3 Glomerulopathy (C3G), Immunoglobulin A Nephropathy (IgAN), or Primary Membranous Nephropathy (PMN)NCT05162066results2024-05-02Percent Change From Baseline in 24-hour uPCR at Week 12Non-randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Terminatedsponsor's stated reason: Sponsor Decision | Drug: BCX9930 | Complement 3 Glomerulopathy, Immunoglobulin A Nephropathy, Membranous Nephropathy | 2 | 2022-09-23actual | — | 2024-05-02 |
| A Long Term Safety Study of BCX7353 in Hereditary AngioedemaNCT03472040results2023-06-18Safety & TolerabilityOpen-label · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2/3 | Completed | Drug: BCX7353 | Hereditary Angioedema, HAE, Prophylaxis | 387 | 2022-04-27actual | — | 2023-06-18 |
| Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in JapanNCT03873116results2021-03-04Part 1: The Rate of Expert-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: BCX7353 capsules, BCX7353 capsules, Placebo oral capsule | Hereditary Angioedema, HAE | 19 | 2021-07-08actual | — | 2024-07-19 |
| A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19NCT03891420number of subjects with treatment emergent adverse events and serious adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Terminatedsponsor's stated reason: Sponsor decision to no longer pursue indications studied in this trial | Drug: Galidesivir, Placebo | COVID-19, Yellow Fever | 24 | 2021-01-31actual | — | 2021-05-27 |
| First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNHNCT04330534Incidence of graded treatment-emergent adverse eventsNon-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: BCX9930, Placebo | Paroxysmal Nocturnal Hemoglobinuria | 168 | 2020-11-11actual | — | 2022-02-17 |
| Safety, PK and Effectiveness of IV Peramivir Versus Oseltamivir in Pediatric Subjects With Uncomplicated InfluenzaNCT02369159results2021-03-23Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.Randomized · Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Peramivir, Oseltamivir | Influenza | 137 | 2019-10-28actual | — | 2021-03-23 |
| A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430NCT03800173results2021-07-23Galidesivir Safety and Tolerability, as Measured by the Number of Participants Experiencing Adverse Events.Randomized · Double-masked · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 1 | Completed | Drug: galidesivir, placebo | Marburg Virus Disease | 32 | 2019-04-30actual | — | 2021-07-23 |
| Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAENCT03485911results2021-03-02Part 1: The Rate of Investigator-confirmed HAE Attacks During Dosing in the Entire 24-week Treatment Period (Day 1 to Day 168)Randomized · Triple-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: BCX7353 capsules, Placebo oral capsule | Hereditary Angioedema, HAE | 121 | 2019-04-10actual | — | 2023-06-26 |
| Study of BCX7353 as a Treatment for Attacks of Hereditary AngioedemaNCT03240133results2021-04-01Proportion of Subjects With Improved or Stable Composite Visual Analog Scale (VAS) ScoreRandomized · Double-masked · TreatmentStatistical Analysis Plan ↗ · Study Protocol ↗ | Phase 2 | Completed | Drug: BCX7353, Placebo | Hereditary Angioedema (HAE) | 58 | 2019-01-29actual | — | 2021-04-01 |
| Safety, PK and Effectiveness of IV Peramivir in Elderly and Higher Risk Subjects With Uncomplicated InfluenzaNCT02635724results2021-03-23Safety and Tolerability, as Measured by the Number of Adverse Events.Open-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 3 | Completed | Drug: Peramivir | Influenza | 74 | Apr 2018actual | — | 2021-03-23 |
| Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary AngioedemaNCT02870972results2021-03-04Number of Confirmed HAE AttacksRandomized · Double-masked · PreventionStudy Protocol ↗ · Statistical Analysis Plan ↗ | Phase 2 | Completed | Drug: BCX7353, Placebo | Hereditary Angioedema (HAE) | 75 | Aug 2017actual | — | 2021-03-23 |
| A Drug-Drug Interaction Study to Evaluate Drug Transporter InteractionsNCT03136237Cmax of probe substrateNon-randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BCX7353, Digoxin, BCX7353 + digoxin, Rosuvastatin, rosuvastatin + BCX7353, Cyclosporine + BCX7353 | Hereditary Angioedema | 54 | 2017-08-15actual | — | 2017-10-26 |
| A Relative Bioavailability Study of Two Formulations of BCX7353NCT03202784Geometric least-squares mean ratio for Cmax for test (blend in capsule) versus reference formulation (API in capsule)Randomized · Open-label · Treatment | Phase 1 | Completed | Drug: BCX7353 | Hereditary Angioedema | 24 | 2017-08-01actual | — | 2020-01-27 |
| An Open-label Drug-Drug Interaction Study to Evaluate the Effect of BCX7353 on Cytochrome P450 Enzyme Activity Using Probe SubstratesNCT02819102Cmax of probe substratesOpen-label · Treatment | Phase 1 | Completed | Drug: BCX7353 and probes | Hereditary Angioedema | 20 | Jun 2016actual | — | 2017-01-31 |
| A Phase 1 Study to Evaluate the Safety, Tolerability and Pharmacokinetics of BCX4430NCT02319772Safety, measured by the frequency and severity of adverse events, laboratory abnormalities and other safety parameters following single (Part 1) and multiple (Part 2) doses of BCX4430Randomized · Quadruple-masked · Treatment | Phase 1 | Completed | Drug: BCX4430, Placebo | Filovirus Infections, Ebola Virus Infection | 94 | Mar 2016actual | — | 2016-07-07 |
| Open-label, Long-term Safety Study of Avoralstat in Subjects With Hereditary AngioedemaNCT02670720Proportion of subjects who discontinue due to a treatment-emergent adverse event, who experience a treatment-emergent serious AE, who experience a Grade 3 or 4 AE and who experience Grade 3 or 4 laboratory abnormalitiesOpen-label · Prevention | Phase 3 | Terminatedsponsor's stated reason: preceding efficacy study of avoralstat in its current formulation was not significant and does not support continued development | Drug: avoralstat | Hereditary Angioedema, HAE | 6 | Feb 2016actual | — | 2016-02-17 |
| 12-Week Safety and Efficacy Study of BCX4161 as an Oral Prophylaxis Against HAE AttacksNCT02303626results2025-11-17The Mean Acute Angioedema Attack RateRandomized · Quadruple-masked · Prevention | Phase 2/3 | Completed | Drug: BCX4161, Placebo | Hereditary Angioedema, HAE | 110 | Jan 2016actual | — | 2025-11-17 |
| First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of BCX7353 in Healthy Western and Japanese VolunteersNCT02448264Adverse eventsRandomized · Double-masked · Treatment | Phase 1 | Completed | Drug: BCX7353, Placebo to match BCX7353 | Hereditary Angioedema | 122 | Nov 2015actual | — | 2016-01-13 |
| Study to Determine How BCX4161 is Metabolized and Eliminated by the BodyNCT02218294Mass balance of BCX4161 after a single oral dose of [14C] BCX4161 based upon radioactivity excreted in urine, expired air and fecesOpen-label · Treatment | Phase 1 | Completed | Drug: BCX4161 | Hereditary Angioedema | 7 | Sep 2014actual | — | 2014-10-29 |
| A Study of the Relative Bioavailability of a New Formulation of BCX4161 and the Effect of Food on BCX4161NCT02125162Plasma pharmacokinetics to assess the relative bioavailability of BCX4161 soft gelatin capsules to hard gelatin capsulesRandomized · Open-label · Treatment | Phase 1 | Completed | Drug: BCX4161 | Hereditary Angioedema | 28 | Jul 2014actual | — | 2014-08-15 |
| Safety and Efficacy of Oral BCX4161 as a Prophylactic Treatment for HAENCT01984788Number of acute angioedema attacksRandomized · Double-masked · Prevention | Phase 2 | Completed | Drug: BCX4161, Placebo | Hereditary Angioedema | 24 | May 2014actual | — | 2014-08-18 |
| A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to InfluenzaNCT00958776results2015-02-12Time to Clinical Resolution (Kaplan-Meier Estimate)Randomized · Double-masked · Treatment | Phase 3 | Terminatedsponsor's stated reason: This study was terminated for futility | Drug: Peramivir+SOC, Placebo+SOC | Cough, Sore Throat, Nasal Congestion, Headache, Fever, Seasonal Influenza | 405 | Nov 2012actual | — | 2015-02-12 |
| Study to Evaluate sUA Lowering Activity, Safety and Efficacy of Oral Ulodesine Added to AllopurinolNCT01265264To evaluate the dose response of ulodesine when combined with Allopurinol on sUA.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: ulodesine, Placebo | Gout, Hyperuricemia, Arthritis, Joint Disease | 279 | Jul 2012actual | — | 2013-11-20 |
| A Randomized, Double-Blind, Dose-Response Study of the Safety and Uric Acid Effects of Oral Ulodesine Added to Allopurinol in Subjects With Gout and Concomitant Moderate Renal InsufficiencyNCT01407874To evaluate the overall safety and tolerability of ulodesine when combined with allopurinol in subjects with moderate renal insufficiency by assessment of percent change from baseline in CD4+ lymphocytes at Day 85.Randomized · Triple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Ulodesine (BCX4208) 5 mg, Ulodesine (BCX4208) 10 mg | Gout, Hyperuricemia, Arthritis, Joint Disease, Renal Insufficiency | 20 | Jul 2012actual | — | 2013-11-20 |
| Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell LymphomaNCT00098332Open-label · Treatment | Phase 1 | Completed | Drug: forodesine hydrochloride | Lymphoma | — | Dec 2010actual | — | 2013-07-10 |
| Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)NCT00640523Overall response rateNon-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: forodesine HCl | Chronic Lymphocytic Leukemia (CLL) | 23 | Nov 2010actual | — | 2012-01-23 |
| Study to Evaluate sUA-Lowering Activity, Safety & PK Interaction of Oral BCX4208 & Allopurinol Admin. in Subjects w/GoutNCT01129648To estimate the dose response relationship of BCX4208 when administered as a monotherapy and in combination with allopurinol on sUA.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Placebo, Allopurinol, Allopurinol, Allopurinol, BCX4208, Allopurinol, Allopurinol, Allopurinol, BCX4208, Allopurinol, Allopurinol, Allopurinol, BCX4208, Allopurinol, Allopurinol, Allopurinol, BCX4208 | Gout | 87 | Nov 2010actual | — | 2012-01-23 |
| A Study to Evaluate the Efficacy and Safety of Intravenous Peramivir in Subjects With Uncomplicated Influenza.NCT01224795To evaluate the efficacy of peramivir administered intravenously compared to placebo on the time to alleviation of clinical symptoms with acute uncomplicated influenza.Randomized · Quadruple-masked · Treatment | Phase 3 | Withdrawn | Drug: Peramivir, Placebo Comparator | Influenza | 0 | Nov 2010actual | — | 2026-06-10 |
| Safety Study of IV Peramivir in Hospitalized Subjects With Confirmed or Suspected InfluenzaNCT00957996results2015-02-12Change From Baseline in Influenza Virus Titer (48 Hours)Randomized · Open-label · Treatment | Phase 3 | Completed | Drug: Peramivir, Peramivir | Seasonal Influenza, Cough, Sore Throat, Nasal Congestion, Myalgia, Headache, Fatigue | 234 | Oct 2010actual | — | 2015-02-12 |
| Study to Evaluate the Urate-Lowering Activity and Safety of Oral BCX4208 Administered in Subjects With GoutNCT00985127To determine the effect of different doses of orally administered BCX4208 on serum uric acid (sUA)levels in subjects with gout.Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: placebo, BCX4208 | Gout | 99 | Sep 2010actual | — | 2012-01-23 |
| Forodesine in the Treatment of Cutaneous T-Cell LymphomaNCT00501735The primary objective of this study is to determine the objective response rate to treatment with oral forodesine in subjects with cutaneous manifestations of CTCL subjects, stages IIB, III, and IVA.Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: Forodesine 200 mg | Cutaneous T-cell Lymphoma (CTCL), | 144 | Jul 2010actual | — | 2012-01-23 |
| A Phase II, Multicenter, Randomized, Placebo -Controlled, Study To Evaluate The Efficacy and Safety Of Intramuscular Peramivir 600 mg In Subjects With Uncomplicated Acute InfluenzaNCT00705406results2015-02-16Time to Alleviation of Symptoms (Kaplan-Meier Estimate)Randomized · Double-masked · Treatment | Phase 2 | Completed | Drug: Peramivir, Placebo | Acute, Uncomplicated Human Influenza | 405 | Apr 2009actual | — | 2015-02-16 |
| Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)NCT00289549Response rate after 2 cyclesof forodesine therapy.Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: forodesine hydrochloride (BCX-1777) | Leukemia, Lymphocytic, Chronic | 8 | Jan 2009actual | — | 2012-02-08 |
| Evaluation of Efficacy and Safety of Peramivir in Adults With Acute Serious or Potentially Life-threatening InfluenzaNCT00453999results2015-02-12Time to Clinical Stability (Kaplan-Meier Estimate)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Peramivir 200 mg, Peramivir 400 mg, Oseltamivir | Influenza | 137 | Sep 2008actual | — | 2015-02-12 |
| Intramuscular Peramivir in Subjects With Uncomplicated Acute InfluenzaNCT00610935results2021-03-17The Time to Alleviation of Clinical Signs and Symptoms of InfluenzaRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: This study was terminated for administrative reasons. | Drug: Peramivir, Placebo | Influenza | 82 | Feb 2008actual | — | 2021-03-17 |
| Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic LeukemiaNCT00289562Open-label · Treatment | Phase 1/2 | Completed | Drug: forodesine hydrochloride (BCX-1777) | B-cell Acute Lymphoblastic Leukemia | 20 | Dec 2007actual | — | 2012-01-20 |
| Evaluation of the Efficacy and Safety of Peramivir in Subjects With Uncomplicated Acute Influenza.NCT00419263results2015-02-12Time to Alleviation of Symptoms (Kaplan-Meier Estimate)Randomized · Quadruple-masked · Treatment | Phase 2 | Completed | Drug: Peramivir 150 mg, Peramivir 300 mg, Placebo | Influenza | 344 | Sep 2007actual | — | 2015-02-12 |
| Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell LeukemiaNCT00095381Determine the sustained effectiveness of IV forodesine hydrochloride infusions in patients with advanced T-cell leukemia (T-ALL or T-PLL)Non-randomized · Open-label · Treatment | Phase 2 | Completed | Drug: forodesine hydrochloride (BCX-1777) | Leukemia, T-Cell | 20 | Mar 2007actual | — | 2012-01-19 |
| Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment RegimensNCT00419081To determine the rate of complete remission for T lymphoblastic leukemia/lymphoma relapsed or refractory patients. The complete remission rate will be evaluated over the three-month Initial Treatment Period.Non-randomized · Open-label · Treatment | Phase 2 | Terminatedsponsor's stated reason: Issues with Manufacturing | Drug: Forodesine Hydrochloride Sterile Solution, 5 mg/mL, Forodesine Hydrochloride Capsules (100 mg) | Leukemia, Lymphoma | 100 | Mar 2007actual | — | 2012-01-23 |
| BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell LymphomaNCT00061880Open-label · Treatment | Phase 1/2 | Completed | Drug: forodesine hydrochloride | Lymphoma | — | Jan 2005actual | — | 2013-05-30 |
| BCX-1777 in Treating Patients With Refractory CancerNCT00073944Open-label · Treatment | Phase 1 | Completed | Drug: forodesine hydrochloride | Cancer | — | Jan 2005actual | — | 2013-05-30 |
| A Study of Peldesine (BCX-34) in HIV-Infected PatientsNCT00002237Treatment | Phase 1 | Completed | Drug: Peldesine | HIV Infections | — | — | — | 2005-06-24 |
| Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or LymphomasNCT00035022Non-randomized · Open-label · Treatment | Phase 1/2 | Completed | Drug: BCX-1777 | Leukemia, Lymphocytic, Lymphoma | 71 | — | — | 2006-01-13 |
| Intramuscular Peramivir for the Treatment of Uncomplicated InfluenzaNCT00486980Randomized · Double-masked | Phase 3 | Withdrawnsponsor's stated reason: This study was withdrawn for administrative reasons. The dose ranging plan for the program was revised". | Drug: Peramivir 150mg, Peramivir 300mg | Influenza | 0 | — | — | 2026-06-01 |
| Oral Berotralstat Expanded Access ProgramNCT04428632expanded access | — | Approved for marketing | Drug: Berotralstat | Hereditary Angioedema, HAE, Prophylaxis | — | — | — | 2020-12-11 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19